A Food and Drug Administration (FDA) advisory panel announced Thursday that a new treatment designed to turn the body's own immune system against deadly prostate cancer tumors is both safe and effective. The panel is recommending that Provenge (sipuleucel-t) from Dendreon Inc. be approved by the FDA for treatment of advanced prostate cancer. The FDA usually follows what the advisory panels recommend. An FDA decision is expected in mid-May.
Provenge was the first vaccine for any cancer shown to extend life. This will be the first immunotherapy approved for treatment of prostate cancer and the second drug ever approved for advanced prostate cancer, after Taxotere. More on this topic next week.
Source: National Prostate Cancer Coalition
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment